Histidine ( DrugBank: Histidine )

3 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2
169	Menkes disease	4
170	Occipital horn syndrome	1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04764383 (ClinicalTrials.gov)	January 1, 2022	18/2/2021	Histaminergic Basis of Fatigue in Multiple Sclerosis	Histaminergic Basis of Fatigue in Multiple Sclerosis	Multiple Sclerosis	Drug: L-Histidine;Drug: Placebo;Drug: Lodosyn	University of Miami	NULL	Withdrawn	18 Years	60 Years	All	0	Phase 2	United States
2	NCT03266965 (ClinicalTrials.gov)	March 23, 2018	4/7/2017	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Multiple Sclerosis	Drug: Carbidopa;Dietary Supplement: L-Histidine	University of Miami	United States Department of Defense	Completed	18 Years	60 Years	All	18	Phase 1	United States

169. Menkes disease

Clinical trials : 7 / Drugs : 7 - (DrugBank : 4) / Drug target genes : 9 - Drug target pathways : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000030626	2014/11/28	28/12/2017	Investigation on the effectiveness of histidine copper treatment of Menkes disease patients		Menkes disease	Weekly,subcutaneous injection of histidine copper (750microgram once) is performed three times per week.It is continued every week until the end of the research during the research period.	Hamamatsu University School of Medicine	NULL	Complete: follow-up complete	Not applicable	Not applicable	Male and Female	2	Not selected	Japan
2	JPRN-UMIN000005259	2011/03/03	18/03/2011	Clinical trial of histidine-copper and diethyldithiocarbamate combination therapy for patients with Menkes disease		Menkes disease	give a dose of copper-histidine and diethyldithiocarbamate	Kobe Unniversitu Graduate School of Medicine	NULL	Complete: follow-up complete	Not applicable	Not applicable	Male and Female	2	Not selected	Japan
3	NCT00811785 (ClinicalTrials.gov)	February 27, 2009	18/12/2008	Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency	Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency	Menkes Disease;Occipital Horn Syndrome;Unexplained Copper Deficiency	Drug: Copper Histidine	Cyprium Therapeutics, Inc.	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH)	Completed	N/A	80 Years	All	93	Phase 3	United States
4	NCT00001262 (ClinicalTrials.gov)	June 1990	3/11/1999	Copper Histidine Therapy for Menkes Diseases	Early Copper Histidine Therapy in Menkes Disease	Kinky Hair Syndrome	Drug: Copper Histidine	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Completed	N/A	N/A	All	60	Phase 1/Phase 2	United States

170. Occipital horn syndrome

Clinical trials : 2 / Drugs : 4 - (DrugBank : 3) / Drug target genes : 9 - Drug target pathways : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00811785 (ClinicalTrials.gov)	February 27, 2009	18/12/2008	Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency	Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency	Menkes Disease;Occipital Horn Syndrome;Unexplained Copper Deficiency	Drug: Copper Histidine	Cyprium Therapeutics, Inc.	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH)	Completed	N/A	80 Years	All	93	Phase 3	United States